Fierce Health Technology June 8, 2020
Broad-panel genomic sequencing may bring down the overall cost of care for cancer patients, a recent CVS study shows.
CVS Health researchers released an analysis on the cost difference between offering cancer patients broad-panel and narrow-panel sequencing at the American Society of Clinical Oncology last month.
The study identified lung cancer 45 patients who were given broad-panel sequencing and 399 who underwent narrow-panel sequencing from January 2018 to March 2019. And they found that while BPS costs more upfront, total costs for cancer care were lower as the genomic testing allowed for more targeted interventions.
Average costs for broad-panel sequencing were $1,977 while narrow-panel sequencing cost on average $819.
However, on average, the six-month per member...
Today's Sponsors
Today's Sponsor